#1 Clinical Trials Search in Europe

Crizanlizumab

Crizanlizumab is an innovative drug being studied in clinical trials for its potential to treat sickle cell disease (SCD) and other conditions. This article summarizes key findings from several clinical trials investigating crizanlizumab’s safety and efficacy in reducing vaso-occlusive crises, improving blood flow, and addressing complications in SCD patients. We’ll also explore its potential applications for other vascular conditions.

Table of Contents

What is Crizanlizumab?

Crizanlizumab, also known by its brand name Adakveo or research code SEG101, is a medication primarily used to treat sickle cell disease (SCD)[1]. It is a type of drug called a monoclonal antibody, which means it’s a laboratory-made protein that targets a specific substance in the body[2].

How Does Crizanlizumab Work?

Crizanlizumab works by targeting a protein called P-selectin. P-selectin plays a role in blood cells sticking to the walls of blood vessels. In sickle cell disease, this sticking can lead to blockages in blood flow, causing pain and other complications. By blocking P-selectin, crizanlizumab helps prevent these blockages[3].

Primary Use: Sickle Cell Disease

Crizanlizumab is primarily used to reduce the frequency of vaso-occlusive crises (VOCs) in patients with sickle cell disease aged 16 years and older. VOCs are painful episodes that occur when sickled red blood cells block blood flow in small blood vessels[1]. These crises can lead to severe pain and may require hospital visits.

Dosage and Administration

Crizanlizumab is typically administered through an intravenous (IV) infusion. The usual dose is 5 mg/kg of body weight. The treatment schedule usually involves:

  • Initial doses at Week 1 and Week 3
  • Subsequent doses every 4 weeks

This schedule may continue for as long as the patient benefits from the treatment[2].

Efficacy in Sickle Cell Disease

Clinical trials have shown that crizanlizumab can significantly reduce the frequency of VOCs in patients with sickle cell disease. This reduction in crises can lead to:

  • Fewer hospitalizations and emergency room visits
  • Reduced days spent in the hospital
  • Improved quality of life for patients

These benefits have been observed in both adult and pediatric patients with SCD[2][1].

Safety and Side Effects

While crizanlizumab has shown significant benefits, like all medications, it can have side effects. Common side effects reported in clinical trials include:

  • Nausea
  • Joint pain (arthralgia)
  • Back pain
  • Fever (pyrexia)
  • Headache

Most side effects are mild to moderate in severity. Serious side effects are less common but can occur[1][4].

Ongoing Research

Researchers continue to study crizanlizumab to better understand its effects and potential uses. Current areas of research include:

  • Long-term safety and efficacy in sickle cell disease
  • Use in pediatric patients (children and adolescents)
  • Combination with other treatments for sickle cell disease
  • Potential use in other conditions involving blood vessel blockages

These ongoing studies help to provide more information about how crizanlizumab can best be used to help patients[2][5].

Potential Future Applications

While crizanlizumab is primarily used for sickle cell disease, researchers are exploring its potential in other conditions. Some areas of investigation include:

  • COVID-19: A study is looking at whether crizanlizumab could help treat the blood vessel complications seen in severe COVID-19 cases[3].
  • Brain Conditions: Researchers are studying if crizanlizumab could help in conditions affecting blood vessels in the brain, such as certain types of stroke and a rare condition called retinal vasculopathy with cerebral leukoencephalopathy (RVCL)[6].
  • Cancer: Early research is exploring whether crizanlizumab, alone or combined with other treatments, could help in treating certain brain cancers and melanoma that has spread to the brain[7].

These potential new uses are still in the research phase and require further study to determine their effectiveness and safety.

Aspect Details
Drug Name Crizanlizumab (also known as SEG101)
Primary Indication Sickle Cell Disease (SCD)
Mechanism of Action P-selectin inhibitor, reducing cell adhesion to blood vessel walls
Main Clinical Benefit Reduction in frequency of vaso-occlusive crises (VOCs)
Age Groups Studied 6 months to adults (varying by study)
Dosing Typically 5 mg/kg intravenously, with varying schedules
Common Side Effects Nausea, joint pain, headache, back pain, fever, upper respiratory infections
Other Potential Applications RVCL, COVID-19 vasculopathy
Key Outcome Measures VOC frequency, hospitalization rates, tissue oxygenation, biomarkers of inflammation and thrombosis
Current Status FDA approved for SCD; ongoing trials for expanded indications and age groups

FAQ

  • What is crizanlizumab and how does it work? Crizanlizumab is a humanized monoclonal antibody that targets P-selectin, a protein involved in blood cell adhesion. By blocking P-selectin, crizanlizumab helps prevent red blood cells and white blood cells from sticking to blood vessel walls, potentially reducing vaso-occlusive crises and improving blood flow in sickle cell disease patients.
  • What is the main purpose of using crizanlizumab in sickle cell disease? The primary purpose of using crizanlizumab in sickle cell disease is to reduce the frequency of vaso-occlusive crises (VOCs). These painful episodes occur when sickled red blood cells block small blood vessels, causing tissue damage and severe pain. Clinical trials aim to demonstrate crizanlizumab's effectiveness in preventing or reducing these crises.
  • What age groups are being studied in crizanlizumab clinical trials? Clinical trials are studying crizanlizumab in various age groups. Some trials focus on adults aged 16 years and older, while others are investigating its use in pediatric patients as young as 6 months old. This wide age range helps researchers understand the drug's safety and efficacy across different stages of sickle cell disease.
  • Are there any potential side effects of crizanlizumab? Common side effects reported in clinical trials include nausea, joint pain, back pain, headache, fever, and upper respiratory tract infections. More serious side effects are being monitored, but overall, crizanlizumab appears to be well-tolerated in most patients. As with any medication, individual responses may vary.
  • Is crizanlizumab being studied for conditions other than sickle cell disease? Yes, crizanlizumab is being investigated for other conditions beyond sickle cell disease. Clinical trials are exploring its potential in treating retinal vasculopathy with cerebral leukoencephalopathy (RVCL) and COVID-19-related vasculopathy. These studies aim to leverage crizanlizumab's ability to improve blood flow and reduce inflammation in various vascular conditions.

Ongoing Clinical Trials on Crizanlizumab

  • Study on Crizanlizumab for Adolescents and Adults with Sickle Cell Disease Experiencing Vaso-Occlusive Crises

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Finland France The Netherlands Spain

  • A Phase 4 Study of Crizanlizumab Treatment for Patients with Sickle Cell Disease Who Previously Participated in Novartis Clinical Trials

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy Spain

Glossary

  • Vaso-occlusive crisis (VOC): A painful episode in sickle cell disease where sickled red blood cells block small blood vessels, causing tissue damage and severe pain. It often requires medical attention and can lead to organ damage if frequent or severe.
  • P-selectin: A protein found on the surface of blood vessels and platelets that plays a role in cell adhesion. It is the target of crizanlizumab, which aims to block its function to prevent blood cells from sticking to vessel walls.
  • Monoclonal antibody: A type of protein made in the laboratory that can bind to specific substances in the body. Crizanlizumab is a monoclonal antibody designed to target P-selectin.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion. PK studies help determine the appropriate dosing of a medication.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and biochemical and physiological effects. PD studies help understand how a drug produces its therapeutic effects.
  • Acute chest syndrome: A serious complication of sickle cell disease characterized by chest pain, fever, and difficulty breathing. It can be life-threatening and requires prompt medical attention.
  • Priapism: A painful and prolonged erection of the penis not associated with sexual arousal. It is a potential complication of sickle cell disease that can lead to erectile dysfunction if not treated promptly.
  • Hydroxyurea: A medication commonly used in sickle cell disease to increase fetal hemoglobin production and reduce the frequency of painful crises. It is often used in combination with other treatments.
  • Retinal vasculopathy with cerebral leukoencephalopathy (RVCL): A rare genetic condition that affects the small blood vessels in the brain and eyes, leading to vision loss, mini-strokes, and dementia. Crizanlizumab is being studied as a potential treatment for this condition.
  • Supply-demand matching (SDM): The balance between oxygen supply and demand in tissues. In sickle cell disease, this balance can be disrupted, leading to tissue hypoxia and organ damage. Improving SDM is a goal of some crizanlizumab studies.

References

  1. https://clinicaltrials.gov/study/NCT04662931
  2. https://clinicaltrials.gov/study/NCT03474965
  3. https://clinicaltrials.gov/study/NCT04435184
  4. https://clinicaltrials.gov/study/NCT03264989
  5. https://clinicaltrials.eu/trial/study-for-patients-with-sickle-cell-disease-using-crizanlizumab-after-completing-a-previous-novartis-study/
  6. https://clinicaltrials.gov/study/NCT04611880
  7. https://clinicaltrials.gov/study/NCT05909618